Positive results from Phase III trial of pembrolizumab in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer

In KEYNOTE-177, patients treated with first-line pembrolizumab had a longer median progression-free survival than those treated with standard of care chemotherapy (mFOLFOX6 or FOLFIRI ± bevacizumab or cetuximab) (16.5 v 8.2 months; HR 0.60; 95% CI 0.45-0.80; p=0.0002).

SPS commentary:

The study will continue to evaluate overall survival, the co-primary endpoint. The above results are due for presentation at the ASCO annual meeting on May 31st 2020.

Biospace Inc.